Developer docs
API playgroundTry for free, no card

Search company profiles

Aerami Therapeutics

Full company profile

uuid0002fd9

Namestring
Aerami Therapeutics
Legal namestring
Aerami Therapeutics Holdings, Inc.
Websiteurl
aerami.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Aerami Therapeutics is a privately-held, clinical-stage pharmaceutical company headquartered in Durham, North Carolina, founded in 2010. The company focuses on developing novel inhaled therapies for the treatment of chronic diseases, with a particular emphasis on respiratory diseases including diabetes-related respiratory complications and other conditions requiring inhalation-based drug delivery. Aerami's stated differentiation rests on advanced drug-device combination delivery systems designed to enable targeted pulmonary therapeutics.

The company operates with a small team of 11-50 employees and has been sustained through venture capital, raising approximately $133 million across nine funding rounds from 2014 through 2022, with disclosed institutional participation from SternAegis and Molex Ventures (which led rounds in 2018 and 2019). Aerami Therapeutics Holdings, Inc. is the legal entity, which filed a Form D with the US SEC in September 2022 for a $20 million exempt securities offering. The leadership team includes Anne C. Whitaker as Chairman of the Board, Lisa Yañez as incoming Chief Executive Officer, and Barry Deutsch as CFO.

Aerami's business model is preclinical/clinical pharmaceutical development: it has no commercially approved products, no disclosed revenue, and no public pricing. Its sole identified end-segment is patients suffering from respiratory diseases requiring inhalation therapeutics, addressed through what the company describes as advanced drug delivery technology. The company's monetization path is contingent on future regulatory approval and commercialization of its inhaled therapeutic candidates rather than current product sales, licensing, or partnership revenue disclosed in available material.

Short descriptiontext

Aerami Therapeutics is a privately-held, clinical-stage pharmaceutical company based in Durham, North Carolina that develops novel inhaled therapies for patients with chronic respiratory diseases, sustained by approximately $133 million in venture funding across nine rounds since 2014.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
inhaled therapeutics, respiratory drug delivery, pulmonary biopharmaceuticals, chronic disease therapies, inhaled formulation development
Industry3 codes
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAHAIAI
Inhalers (MDI/DPI/SMI)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Medicinal and Botanical Manufacturing325411
Product category
Inhaled Respiratory Therapeutics
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aerami Therapeutics is a clinical-stage biopharmaceutical company developing inhaled drug therapies for chronic and respiratory diseases. The company focuses on novel pulmonary drug delivery systems to treat conditions requiring targeted inhaled administration. It is a private, for-profit entity headquartered in Durham, USA, with 11-50 employees.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Aerami Therapeutics is a pharmaceutical company based in Durham that focuses on developing treatments for respiratory diseases. Based on the available source material, no specific named products, modules, or branded offerings were identified.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based specialty pharmaceutical company focused on inhaled drug delivery for respiratory diseases. Aerami's inhaled respiratory platform is directly comparable in mechanism of delivery and therapeutic focus.

TypeDirect peer
Description

Clinical-stage US biotech developing inhaled therapies for respiratory and infectious diseases using proprietary particle engineering. Comparable to Aerami in stage, respiratory focus, and inhaled delivery technology.

3TFF Pharmaceuticals
TypeDirect peer
Description

Clinical-stage company developing inhaled and intranasal therapeutics using a thin-film formulation platform. Comparable in route of delivery and small-cap clinical-stage profile to Aerami.

TypeEmerging player
Description

Emerging biotech developing an inhaled antibody platform for respiratory infectious diseases. Comparable as a niche inhaled therapeutics company, though with a narrower biologic-only focus than Aerami.

5Civitas Therapeutics
TypeEmerging player
Description

Was a US inhaled therapeutics company (acquired by Acorda in 2014) that developed ARCUS inhaled dry-powder platform. Provides a directly comparable device-plus-drug inhaled respiratory model that ultimately transacted with a larger pharma.

6Aradigm Corporation
TypeEmerging player
Description

Was a US specialty pharma developing inhaled liposomal therapies (acquired by Grifols for AAT deficiency). Closely comparable to Aerami in inhaled respiratory / AAT focus and small-cap development profile.

TypeBroad incumbent
Description

Global pharma major with one of the largest respiratory franchises (Advair/Relvar/Trelegy). Represents the dominant incumbent in inhaled respiratory therapeutics against which Aerami's niche technology must compete or partner.

TypeBroad incumbent
Description

Global pharma major with a major respiratory and inhaled biologics franchise (Symbicort, Fasenra). Comparable as both a potential competitor and a likely acquisition/licensing partner for Aerami's platform.

TypeBroad incumbent
Description

Large generic and specialty pharma with a substantial respiratory inhalation product portfolio (Dulera, Yupelri, Perforomist). Comparable as a competing developer of generic and branded inhaled respiratory therapies.

TypeRegional player
Description

US-based specialty pharma focused on inhaled antibiotics and pulmonary delivery (e.g., Arikayce). Comparable in the US market as a small-cap inhaled therapeutics developer that has successfully commercialized a respiratory product.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aerami Therapeutics

Inhaled Respiratory Therapeuticsaerami.com

Aerami Therapeutics is a privately-held, clinical-stage pharmaceutical company based in Durham, North Carolina that develops novel inhaled therapies for patients with chronic respiratory diseases, sustained by approximately $133 million in venture funding across nine rounds since 2014.

What Aerami Therapeutics does

Aerami Therapeutics is a privately-held, clinical-stage pharmaceutical company headquartered in Durham, North Carolina, founded in 2010. The company focuses on developing novel inhaled therapies for the treatment of chronic diseases, with a particular emphasis on respiratory diseases including diabetes-related respiratory complications and other conditions requiring inhalation-based drug delivery. Aerami's stated differentiation rests on advanced drug-device combination delivery systems designed to enable targeted pulmonary therapeutics.

The company operates with a small team of 11-50 employees and has been sustained through venture capital, raising approximately $133 million across nine funding rounds from 2014 through 2022, with disclosed institutional participation from SternAegis and Molex Ventures (which led rounds in 2018 and 2019). Aerami Therapeutics Holdings, Inc. is the legal entity, which filed a Form D with the US SEC in September 2022 for a $20 million exempt securities offering. The leadership team includes Anne C. Whitaker as Chairman of the Board, Lisa Yañez as incoming Chief Executive Officer, and Barry Deutsch as CFO.

Aerami's business model is preclinical/clinical pharmaceutical development: it has no commercially approved products, no disclosed revenue, and no public pricing. Its sole identified end-segment is patients suffering from respiratory diseases requiring inhalation therapeutics, addressed through what the company describes as advanced drug delivery technology. The company's monetization path is contingent on future regulatory approval and commercialization of its inhaled therapeutic candidates rather than current product sales, licensing, or partnership revenue disclosed in available material.

Aerami Therapeutics firmographics

Firmographics
Name
Aerami Therapeutics
Legal name
Aerami Therapeutics Holdings, Inc.
Website
https://aerami.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Aerami Therapeutics is a privately-held, clinical-stage pharmaceutical company based in Durham, North Carolina that develops novel inhaled therapies for patients with chronic respiratory diseases, sustained by approximately $133 million in venture funding across nine rounds since 2014.
Ownership category
akta.pro rank

Aerami Therapeutics industry classification

Industry
Product category
Inhaled Respiratory Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)
akta.pro industry
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAHAIAI
Inhalers (MDI/DPI/SMI)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Inhaled therapeutics
  • Respiratory drug delivery
  • Pulmonary biopharmaceuticals
  • Chronic disease therapies
  • Inhaled formulation development

Where Aerami Therapeutics is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Markets served

Aerami Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Aerami Therapeutics product offering

Product offering

Core offering

Aerami Therapeutics is a clinical-stage biopharmaceutical company developing inhaled drug therapies for chronic and respiratory diseases. The company focuses on novel pulmonary drug delivery systems to treat conditions requiring targeted inhaled administration. It is a private, for-profit entity headquartered in Durham, USA, with 11-50 employees.

Product overview

Aerami Therapeutics is a pharmaceutical company based in Durham that focuses on developing treatments for respiratory diseases. Based on the available source material, no specific named products, modules, or branded offerings were identified.

Differentiator

Problem solved

Functional benefit

Companies that use Aerami Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Aerami Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Aerami Therapeutics partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights3 records

Aerami Therapeutics competitors and assessment

Company assessment

Direct peers

  • Vectura Group: UK-based specialty pharmaceutical company focused on inhaled drug delivery for respiratory diseases. Aerami's inhaled respiratory platform is directly comparable in mechanism of delivery and therapeutic focus.
  • Pulmatrix: Clinical-stage US biotech developing inhaled therapies for respiratory and infectious diseases using proprietary particle engineering. Comparable to Aerami in stage, respiratory focus, and inhaled delivery technology.
  • TFF Pharmaceuticals: Clinical-stage company developing inhaled and intranasal therapeutics using a thin-film formulation platform. Comparable in route of delivery and small-cap clinical-stage profile to Aerami.

Emerging players

  • Inhalon Biopharma: Emerging biotech developing an inhaled antibody platform for respiratory infectious diseases. Comparable as a niche inhaled therapeutics company, though with a narrower biologic-only focus than Aerami.
  • Civitas Therapeutics: Was a US inhaled therapeutics company (acquired by Acorda in 2014) that developed ARCUS inhaled dry-powder platform. Provides a directly comparable device-plus-drug inhaled respiratory model that ultimately transacted with a larger pharma.
  • Aradigm Corporation: Was a US specialty pharma developing inhaled liposomal therapies (acquired by Grifols for AAT deficiency). Closely comparable to Aerami in inhaled respiratory / AAT focus and small-cap development profile.

Broad incumbents

  • GSK: Global pharma major with one of the largest respiratory franchises (Advair/Relvar/Trelegy). Represents the dominant incumbent in inhaled respiratory therapeutics against which Aerami's niche technology must compete or partner.
  • AstraZeneca: Global pharma major with a major respiratory and inhaled biologics franchise (Symbicort, Fasenra). Comparable as both a potential competitor and a likely acquisition/licensing partner for Aerami's platform.
  • Viatris (Mylan Upjohn): Large generic and specialty pharma with a substantial respiratory inhalation product portfolio (Dulera, Yupelri, Perforomist). Comparable as a competing developer of generic and branded inhaled respiratory therapies.

Regional players

  • Insmed: US-based specialty pharma focused on inhaled antibiotics and pulmonary delivery (e.g., Arikayce). Comparable in the US market as a small-cap inhaled therapeutics developer that has successfully commercialized a respiratory product.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Aerami Therapeutics social profiles

Digital presence

Aerami Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aerami Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Aerami Therapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aerami Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aerami Therapeutics

What does Aerami Therapeutics do?

Aerami Therapeutics is a clinical-stage biopharmaceutical company developing inhaled drug therapies for chronic and respiratory diseases. The company focuses on novel pulmonary drug delivery systems to treat conditions requiring targeted inhaled administration. It is a private, for-profit entity headquartered in Durham, USA, with 11-50 employees.

Is Aerami Therapeutics a public or private company?

Aerami Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aerami Therapeutics founded?

Aerami Therapeutics was founded in 2010. It employs 11 to 50 people.

Where is Aerami Therapeutics based?

Aerami Therapeutics is headquartered in Durham, United States, in the North America region.

Who are Aerami Therapeutics's main competitors?

Direct peers on record are Vectura Group, Pulmatrix and TFF Pharmaceuticals. Emerging players are Inhalon Biopharma, Civitas Therapeutics and Aradigm Corporation. Broad incumbents are GSK, AstraZeneca and Viatris (Mylan Upjohn). Insmed is listed as a regional player.

Does Aerami Therapeutics have an API?

No public API is recorded for Aerami Therapeutics.

What industry is Aerami Therapeutics in?

Aerami Therapeutics's product category is Inhaled Respiratory Therapeutics. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals, with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 32541.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsAerami Therapeutics shuts down without explanationAerami Therapeutics, a Durham biopharmaceutical company, shut down abruptly after raising over $80 million from 2015 to 2023. The company had been developing an inhaled imatinib for pulmonary hypertension, with a Phase 1 study completed and a planned Phase 2. No explanation was given for the closure.GlobeNewswireAerami Therapeutics to Present New Lung Deposition Modeling Data for AER-901, in Development for Pulmonary Hypertension, at the American Thoracic Society 2024 International ConferenceAerami Therapeutics will present new lung deposition modeling data for AER-901 at the ATS 2024 conference in San Diego. The data compares AER-901's deposition to a hypothetical dry powder inhaled imatinib in pulmonary hypertension patients and healthy volunteers. The company also plans to present its uniPHied platform trial design for Phase 2 evaluation.GlobeNewswireAerami Therapeutics to Present Data Supporting AER-901 Dosing Regimen at CHEST 2023Aerami Therapeutics will present pharmacokinetic modeling data for AER-901 at CHEST 2023, supporting dose selection for the planned Phase 2 uniPHied trial in PH-ILD and PAH. The data extend findings from the completed Phase 1 trial and were included in the updated IND application in Q3 2023.GlobeNewswireAerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO and Expands Management Team as Lead Asset AER-901 (inhaled imatinib) Advances Toward Phase 2 in Pulmonary HypertensionAerami Therapeutics appointed Joshua Ziel as COO and interim CEO, and added Gary Burgess as CMO and Sarah Fritchley as SVP of Clinical Development and Operations. The appointments support the planned Phase 2 trial of AER-901 for pulmonary hypertension, with the trial expected to enroll 80-100 patients.GlobeNewswireAerami Therapeutics Announces Pharmacokinetic Data Demonstrating the Potential of AER-901 (Inhaled Imatinib) to Achieve Therapeutic Levels at Low Inhaled Doses for Treatment of Pulmonary HypertensionAerami Therapeutics announced pharmacokinetic data from AER-901 (inhaled imatinib) studies, showing lung exposure nearly 10-fold higher than oral imatinib. The company plans to update its IND application to initiate a Phase 2 proof-of-concept trial in mid-2023 for pulmonary hypertension.GlobeNewswireAerami Therapeutics to Present Pharmacokinetic Data Supporting AER-901 (Inhaled Imatinib) for Pulmonary Hypertension at the 2023 American Thoracic Society (ATS) International ConferenceAerami Therapeutics will present non-clinical pharmacokinetic data and Phase 1 trial results for AER-901 at the 2023 ATS conference. The data show therapeutic lung levels at low inhaled doses, supporting Phase 2 development for pulmonary arterial hypertension and PH-ILD. The company aims to achieve similar efficacy to oral imatinib with a better safety profile.American City Business JournalsAerami Therapeutics CEO Lisa Yañez dies in crash in Chapel HillLisa Yañez, CEO of Durham-based biopharmaceutical company Aerami Therapeutics, died in a car crash in Chapel Hill. The crash occurred this week, and the company had recently appointed her as CEO.BioSpaceAerami Therapeutics Mourns the Sudden Loss of Chief Executive Officer Lisa YañezAerami Therapeutics announced the sudden death of CEO Lisa Yañez on May 2, 2023. Anne Whitaker, Executive Chairwoman, will lead the company immediately. The company will continue its pulmonary hypertension clinical programs.GlobeNewswireAerami Therapeutics Mourns the Sudden Loss of Chief Executive Officer Lisa YañezAerami Therapeutics announced the sudden death of CEO Lisa Yañez on May 2, 2023. Anne Whitaker, Executive Chairwoman, will lead the company immediately. The company will continue its pulmonary hypertension clinical programs.GlobeNewswireAerami Therapeutics to Host Virtual Investor Day with Leading Experts in Pulmonary Hypertension as AER-901 (Inhaled Imatinib) Advances Toward Phase 2Aerami Therapeutics will host a virtual Investor Day on April 11, 2023, to discuss its lead asset AER-901 (inhaled imatinib) for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The event features presentations from experts and a Q&A session, with AER-901 in development under an exclusive global license from Vectura Ltd.